Author

R. Meering

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Krippner-Heidenreich· 1 shared B. A. van der Reijden· 1 shared B. M. H. Heuts· 1 shared D. Gilissen· 1 shared J. H. A. Martens· 1 shared J. H. Jansen· 1 shared M. Vermeulen· 1 shared O. Heidenreich· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Krippner-Heidenreich

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

The neuronal homeobox transcription factor HMX3 is a crucial vulnerability factor in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia

S. Arza-Apalategi, B. M. H. Heuts, S. M. Bergevoet, R. Meering, D. Gilissen, P. W. T. C. Jansen, A. Krippner-Heidenreich, P. J. M. Valk, M. Vermeulen, O. Heidenreich, T. Haferlach, J. H. Jansen, J. H. A. Martens, B. A. van der Reijden

The paper identifies HMX3 as a critical vulnerability in MECOM-negative KMT2A::MLLT3 AML, showing it promotes proliferation and blocks differentiation.

bioRxiv · Nov 7, 2023 · PreprintCancer Biology